ESR1 and breast carcinoma: In addition to inhibiting IK channels, TRAM-34 directly interacted with estrogen receptors in a manner similar to 17β-estradiol, thereby enhancing progesterone receptor mRNA expression, reducing estrogen receptor α mRNA expression, and inhibiting the binding of estrogen to its receptor, leading to increased breast cancer cell proliferation [173].